Anvisa changes indications for the use of dengue vaccine



The dengue vaccine, called Dengvaxia, increases the risk of hospitalization or severe dengue from people who have never had contact with the virus at the first infection. On the other hand, efficiency is greater when applied to people who have already presented a certain subtype of the disease.

These findings, obtained after five years of monitoring, prompted the National Sanitary Surveillance Agency (Anvisa) to announce the change in vaccine insertion.

Three changes were made to the Dengvaxia vaccine package. The first, in the sense of limiting the use for "seropositive persons", referring to those who have had dengue and live in endemic areas.

The second amendment contains a clearer definition in the text of what is considered an "endemic area": ​​where at least 70% of people or more have been in contact with the virus.

Finally, it contains the contraindication to the use of the vaccine for people who have never had dengue (seronegative).

"For the approval of these changes, Anvisa believed that the vaccine has been shown to be effective in preventing a new episode of dengue for people who have had any form of the disease, another decisive factor is that Dengvaxia is the only approved dengue. Vaccine is in Brazil, which is suffering from epidemics of the disease on a seasonal basis, "informed Anvisa by letter and stated that these changes are in line with the recommendations of the World Health Organization. Health (WHO).

edition: Sabrina Craide


Source link

Leave a Reply